What was Edwards Lifesciences Corp's revenue in fiscal 2025?

Edwards Lifesciences Corp reported revenue of $6.07B for fiscal 2025, up 11.5% from fiscal 2024.

What is Edwards Lifesciences Corp's net margin?

Operating margin was 20.8% and net margin was 17.7%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

What is Edwards Lifesciences Corp's diluted EPS?

Diluted EPS was $1.83, down 73.7% from the prior year.

Are Edwards Lifesciences Corp insiders buying or selling shares?

Over the past 12 months, insiders reported 53 open-market sales totalling $27.7M on Form 4.

Which institutions hold Edwards Lifesciences Corp stock?

1,953 institutions reported holding Edwards Lifesciences Corp shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Overview

Edwards Lifesciences Corp

EWNYSEHealth CareOrthopedic, Prosthetic & Surgical Appliances & SuppliesCIK 0001099800Large-cap benchmark

Latest 10-K: FY2025, filed Feb 25, 2026 · Open the 10-K (Inline XBRL) ↗

Ask about EW in Workspace

Revenue: $6.07B; 11.5%YoYup from FY2024; TotalRevenue
Gross profit: $4.73B; 9.5%YoYup from FY2024; GrossProfit
Operating income: $1.26B; 8.3%YoYdown from FY2024; OperatingIncome
Net income: $1.07B; 74.3%YoYdown from FY2024; NetIncome
Diluted EPS: $1.83; 73.7%YoYdown from FY2024; EPSDiluted
Diluted shares: 585.8M; 2.3%YoYdown from FY2024; WeightedAvgSharesDiluted

At a glance

Growth

Edwards Lifesciences Corp reported revenue of $6.07B for fiscal 2025, up 11.5% from fiscal 2024.
Revenue grew faster than the median S&P 500 member in 4 of the last 5 fiscal years.

Profitability

Operating margin was 20.8% and net margin was 17.7%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Per share

Diluted EPS was $1.83, down 73.7% from the prior year.

Insiders & holders

Over the past 12 months, insiders reported 53 open-market sales totalling $27.7M on Form 4.
1,953 institutions reported holding Edwards Lifesciences Corp shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Written from the filed figures on this page by fixed rules — no AI.

Data as of Oct 31, 2026 · Sources: SEC EDGAR 10-K, Form 4, 13F

Quick answers

What was Edwards Lifesciences Corp's revenue in fiscal 2025?: Edwards Lifesciences Corp reported revenue of $6.07B for fiscal 2025, up 11.5% from fiscal 2024.
What is Edwards Lifesciences Corp's net margin?: Operating margin was 20.8% and net margin was 17.7%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.
What is Edwards Lifesciences Corp's diluted EPS?: Diluted EPS was $1.83, down 73.7% from the prior year.
Are Edwards Lifesciences Corp insiders buying or selling shares?: Over the past 12 months, insiders reported 53 open-market sales totalling $27.7M on Form 4.
Which institutions hold Edwards Lifesciences Corp stock?: 1,953 institutions reported holding Edwards Lifesciences Corp shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Data as of Oct 31, 2026 · Sources: SEC EDGAR 10-K

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Chip: YoY change.

Income Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Revenue	$6.07B11.5%up Benchmark median 6.4%	$5.44B8.6%up Benchmark median 4.5%	$5.01B12.2%up Benchmark median 4.8%	$4.46B14.7%down Benchmark median 10.3%	$5.23B19.3%up Benchmark median 13.8%	3.8% Benchmark median 6.6%
Gross Profit Median of 315 / 498	$4.73B9.5%up Benchmark median 6.8%	$4.32B7.2%up Benchmark median 5.5%	$4.03B7.8%up Benchmark median 5.2%	$3.74B6.1%down Benchmark median 8.3%	$3.98B20.5%up Benchmark median 15.7%	4.4% Benchmark median 6.2%
Operating Income Median of 373 / 498	$1.26B8.3%down Benchmark median 7.3%	$1.38B5.3%up Benchmark median 7.4%	$1.31B12.6%down Benchmark median 4.9%	$1.50B11.4%down Benchmark median 7.5%	$1.69B88.3%up Benchmark median 23.5%	-7.0% Benchmark median 7.2%
Net Income	$1.07B74.3%down Benchmark median 4.8%	$4.17B197.7%up Benchmark median 5.7%	$1.40B7.9%down Benchmark median 1.9%	$1.52B1.3%up Benchmark median 1.3%	$1.50B82.5%up Benchmark median 33.9%	-8.1% Benchmark median 4.1%
EPS (Diluted)	$1.8373.7%down Benchmark median 6.2%	$6.97203.0%up Benchmark median 7.9%	$2.305.7%down Benchmark median 1.9%	$2.442.5%up Benchmark median 1.5%	$2.3883.1%up Benchmark median 34.8%	-6.4% Benchmark median 5.6%

Balance Sheet

5 annual periods

Chip: YoY change.

Balance Sheet, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Total Assets	$13.70B4.9%up Benchmark median 5.6%	$13.06B39.4%up Benchmark median 3.4%	$9.36B12.9%up Benchmark median 4.1%	$8.29B2.5%down Benchmark median 2.2%	$8.50B17.5%up Benchmark median 6.7%	12.7% Benchmark median 4.7%
Total Liabilities Median of 357 / 498	$3.36B12.3%up Benchmark median 6.4%	$2.99B13.2%up Benchmark median 1.9%	$2.64B6.4%up Benchmark median 2.9%	$2.49B6.8%down Benchmark median 2.0%	$2.67B0.1%up Benchmark median 5.2%	5.9% Benchmark median 4.4%
Stockholders' Equity	$10.34B2.7%up Benchmark median 6.8%	$10.06B49.8%up Benchmark median 5.4%	$6.72B15.7%up Benchmark median 7.3%	$5.81B0.5%down Benchmark median 2.5%	$5.84B27.6%up Benchmark median 9.0%	15.4% Benchmark median 6.1%
Cash & Equivalents	$2.94B3.5%down Benchmark median 5.2%	$3.05B168.9%up Benchmark median 1.9%	$1.13B47.2%up Benchmark median 6.7%	$0.77B10.9%down Benchmark median -8.6%	$0.86B27.1%down Benchmark median -2.9%	35.8% Benchmark median 2.0%
Total Debt	$598.30M^†0.1%up Benchmark median 2.1%	$597.70M^†0.1%up Benchmark median 0.2%	$597.00M^†0.1%up Benchmark median 0.3%	$596.30M^†0.1%up Benchmark median 0.1%	$595.70M^†0.1%up Benchmark median -0.1%	0.1% Benchmark median 4.3%

† Sum of short-term and long-term debt; the company files no total-debt line.

Cash Flow Statement

5 annual periods

Chip: YoY change.

Cash Flow Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Operating Cash Flow	$1.60B194.2%up Benchmark median 6.3%	$0.54B39.5%down Benchmark median 4.8%	$0.90B26.5%down Benchmark median 9.9%	$1.22B29.7%down Benchmark median -0.7%	$1.73B64.3%up Benchmark median 10.7%	-2.0% Benchmark median 7.0%
Capital Expenditures	$260.20M3.1%up Benchmark median 5.4%	$252.40M0.2%down Benchmark median 2.8%	$253.00M3.4%up Benchmark median 11.3%	$244.60M24.9%down Benchmark median 14.0%	$325.80M20.0%down Benchmark median 8.1%	-5.5% Benchmark median 9.0%
Free Cash Flow Median of 378 / 498	$1.33B360.5%up Benchmark median 7.3%	$0.29B54.9%down Benchmark median 6.1%	$0.64B34.0%down Benchmark median 8.8%	$0.97B30.8%down Benchmark median -11.3%	$1.41B117.3%up Benchmark median 10.2%	-1.3% Benchmark median 4.9%

n/m: not meaningful — the base (the prior year, or the first year for the CAGR) was zero or negative, or a per-share figure’s share basis changed (stock split). “—” means the figure is not available.

Benchmark median = median of the companies in the benchmark universe on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Each median uses every member that reports the line item; where fewer than 80% do (banks and insurers file no gross profit), the row names how many. Published where at least 250 companies report it. Updated 2026-10-27. This compares reported figures, not share-price returns. Methodology

Ratios & valuation

FY2025

Every ratio read two ways: Wall Street’s popular formula and the value investor’s stricter one. Same question, same unit. Pick a ratio.

Valuation · Earnings yield

What a dollar of market value earned

2.1%

Wall Street

on net earnings

FY2024 9.4%

2.7%

Value investor

on free cash flow

FY2024 0.7%

Gap +0.6 pts: Value-investor figure 0.6 points higher

How it’s calculated

Wall Street · on net earnings

Diluted EPS ÷ fiscal-year-end share price (1 ÷ P/E)

pe_ratio (ratio table)

P/E 46.6×

Value investor · on free cash flow

(Operating cash flow − capital expenditures) ÷ market capitalisation (fiscal-year-end close × weighted-average diluted shares)

free cash flow ÷ market cap

Each ratio measures one thing two ways, in the same unit: the popular formula, then a stricter one, so a lower figure is the stricter reading. Gap = value-investor figure minus Wall Street figure, from the figures shown.

Price-based ratios use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Each ratio’s formulas are under “How it’s calculated”.

Cash & capital allocation

Where the cash went in FY2025, from the 10-K cash flow statement.

Operating cash flow: $1.60B
Capex: $260.20M
Free cash flow: $1.33B
R&D: $1.08B
Buybacks: $893.40M
Dividends: —
Debt repaid: —
Debt issued: —
Net debt change: —

Uses of operating cash flow, FY2025

Buybacks56.0%
Capex16.3%

Each use is shown against operating cash flow on its own; the uses overlap.

Free cash flow by year

FY21$1.41B
FY22$973.60M
FY23$642.80M
FY24$289.90M
FY25$1.33B

Buybacks by year

FY21$512.80M
FY22$1.73B
FY23$879.60M
FY24$1.16B
FY25$893.40M

Smart money

Who is trading and holding Edwards Lifesciences Corp, from Form 4, 13F and 13D/13G filings.

Insiders

Insider activity · past 12 months

Open-market trades reported on Form 4 in the past 365 days.

Buys: 0; none reported
Sales: 53; 9 insiders
Value sold: $27.7M
Shares sold: 331,564.51
Net shares: -331,564.51; bought minus sold
Last trade: Sep 11, 2026

Purchases 0% of valueSales 100% of value

Latest open-market insider trades from Form 4
Insider	Type	Date	Shares	Price	Value	Filing
Lippis Daniel J.CVP, TAVR	Sell	Sep 11, 2026	619	$87.51	$54,169	View filing on SEC EDGAR
Dahl Andrew M.SVP, Corporate Controller	Sell	Aug 31, 2026	544	$91.06	$49,537	View filing on SEC EDGAR
Bruls AnnetteCVP, EMEACLA	Sell	Aug 28, 2026	2,644	$89.98	$237,907	View filing on SEC EDGAR

See plans

Open-market purchases (code P) and sales (code S) only. Grants, option exercises and tax withholding are excluded. Sales may be made under pre-arranged Rule 10b5-1 plans.

Ownership

Largest institutional holders

13F

Quarter ended Jun 30, 2026; change versus Mar 31, 2026.

Institutions reporting: 1,953
Top 3 hold: 15.4%; of 585.80M diluted shares, FY2025 10-K

Top 3 holders, share of diluted sharesof 100%

Vanguard Capital Management6.4%
37,615,952 sh · $3.4BTrimmed 0.3%13F-HR · Jun 30, 2026 on SEC EDGAR
Vanguard Portfolio Management4.5%
26,411,402 sh · $2.4BAdded 0.0%13F-HR · Jun 30, 2026 on SEC EDGAR
STATE STREET CORP4.5%
26,321,940 sh · $2.4BAdded 0.1%13F-HR · Jun 30, 2026 on SEC EDGAR

See plans

Some filers' amendments could not be read, so a few holders may be counted twice.

Bars: share of diluted shares on a shared scale; the tick marks 5%. 13F filings are due 45 days after quarter end, so this is the latest fully reported quarter. Amended filings are counted once.

Blockholders, 5% and over

13D/G

SC 13D / 13G, latest filing per filer.

Filers at 5%+: 3
Combined: 20.3%; sum of latest filings
Activist (13D): 0

5%+ filers, share of the class as filedof 100%

Vanguard Capital Management7.54%
Passive · 13GSC 13G · Apr 29, 2026 on SEC EDGAR
BlackRock, Inc.7.5%
Passive · 13GLast filed 1 yr agoSC 13G/A · Oct 17, 2025 on SEC EDGAR
Wellington Group Holdings LLP5.23%
Passive · 13GLast filed 1 yr agoSC 13G · Nov 8, 2024 on SEC EDGAR

No filer switched from a passive 13G to an activist 13D in the last 365 days.

Percent of the class as each filer last reported it; filings older than a year may no longer reflect the stake. Latest filing per filer within three years; a later filing reporting 0% removes the filer.

Full history, every insider and 13F filer, 13D/G activist stakes, and webhooks are on Institutional.

See Institutional

Smart money

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Restatement Radar

6 numbers Edwards Lifesciences Corp later changed — same XBRL tag, both filings linked.

numbers changed: 6
restating filings: 4
came with an amendment or a non-reliance notice: 0

Jul 31, 2024 · 10-Q
changed 2 numbers
No amendment filed
Open filing
- Operating incomeQ2 2023$327.2M restated to $263.5M−19.5%
  As reported · Jul 28, 2023us-gaap:OperatingIncomeLoss
- Pretax incomeQ2 2023$338.5M restated to $275.1M−18.7%
  As reported · Jul 28, 2023us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Feb 28, 2025 · 10-K
changed 2 numbers
No amendment filed
Open filing
- Total revenueFY 2022$5.4B restated to $4.5B−17.1%
  As reported · Feb 13, 2023us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 20.6% too low.
- Total revenueQ2 2023$1.5B restated to $1.3B−16.4%
  As reported · Jul 28, 2023us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 19.6% too low.
May 6, 2025 · 10-Q
changed 1 number
No amendment filed
Open filing
- Total revenueQ1 2024$1.6B restated to $1.3B−16.8%
  As reported · Apr 29, 2024us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 20.2% too low.
Feb 25, 2026 · 10-K
changed 1 number
No amendment filed
Open filing
- Total revenueFY 2023$6B restated to $5B−16.6%
  As reported · Feb 12, 2024us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxAny P/S built on the original was 19.9% too low.

EW is not the only one.

See every restatement we've found across the market — or get an alert the next time EW revises a number.

Restatement Radar Alert me

Restatements are detected by comparing every vintage of a fact across all of Edwards Lifesciences Corp's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows EW's most significant revisions, and a figure absent from it has not been certified as unrevised.

Peers, filings & research

Sector Peers

UNITEDHEALTH GROUP INC

MRK· Health Care

Merck & Co., Inc.

TMO· Health Care

THERMO FISHER SCIENTIFIC INC.

ABT· Health Care

ABBOTT LABORATORIES

ISRG· Health Care

INTUITIVE SURGICAL INC

AMGN· Health Care

AMGEN INC

Recent SEC filings

The six newest, periodic reports and 8-Ks together. Dates are SEC filing dates.

All filings on EDGAR

Six most recent SEC filings, newest first
Form	Filing	Filed	Document
8-K	Current report (material events) · Event dated Aug 25, 2026 0001099800-26-000048 · accepted 20:15 UTC	Aug 28, 2026	Open	Filed Aug 28, 2026 · 0001099800-26-000048
10-Q	Quarterly report · Quarter ended Jun 30, 2026 0001099800-26-000043 · accepted 20:14 UTC	Aug 4, 2026	Open	Filed Aug 4, 2026 · 0001099800-26-000043
8-K	Current report (material events) · Event dated Jul 23, 2026 0001099800-26-000038 · accepted 20:29 UTC	Jul 23, 2026	Open	Filed Jul 23, 2026 · 0001099800-26-000038
10-K	Annual report · Fiscal year ended Dec 31, 2025 0001099800-26-000009 · accepted 21:11 UTC	Feb 25, 2026	Open	Filed Feb 25, 2026 · 0001099800-26-000009
10-Q/A	Quarterly report amendment · Quarter ended Jun 30, 2003 0001104659-03-024123 · accepted 11:05 UTC	Oct 30, 2003	Open	Filed Oct 30, 2003 · 0001104659-03-024123
10-K/A	Annual report amendment · Fiscal year ended Dec 31, 2002 0001104659-03-024121 · accepted 11:03 UTC	Oct 30, 2003	Open	Filed Oct 30, 2003 · 0001104659-03-024121

“Open” goes to the Inline XBRL viewer when the filing has one, else the primary document. The accession opens the EDGAR index.

Research Reports

No published research on EW yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on EW and publish the result to your public profile.

Browse the research catalog Generate one with your agent

The data behind this page

27 tables, history 1993–present. Every figure above is a row you can query.

Fundamentals

Standardized financial facts, ratios and filings.

fact: 121.4Mrows
ratio: 15.8Mrows
filing: 3.71Mrows
entity: 33,316rows

350+ standard concepts.

Built from these SEC forms

10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QT
10-QT/A
20-F
20-F/A
40-F
40-F/A
8-K
8-K/A
6-K
6-K/A
S-1
S-1/A
S-3
S-3/A
S-4
S-4/A
S-11
S-11/A
F-1
F-1/A
F-3
F-3/A
F-4
F-4/A
POS AM
10-KSB
10-KSB/A
10-QSB
10-QSB/A
DEF 14Asoon
DEF 14Csoon
DEFA14Asoon
PRE 14Asoon
DEFM14Asoon
425soon
SC TO-Tsoon
SC TO-Isoon
SC 14D9soon
SC 13E3soon
CORRESPsoon
NT 10-Ksoon
NT 10-Qsoon
NT 20-Fsoon
N-PORT-Psoon

Smart money

Insider and institutional filings.

institutional_holding: 88.6Mrows
insider_transaction: 12.1Mrows
insider_filing: 5.55Mrows
insider_ownership: 1.98Mrows

109M+ smart-money rows in all.

Built from these SEC forms

Form 3
Form 3/A
Form 4
Form 4/A
Form 5
Form 5/A
13F-HR
13F-HR/A
13F-NT
13F-NT/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
Form 144
Form 144/A

One real fact row for Edwards Lifesciences Corp

Fact receiptOperatingCashFlow

Operating cash flow · FY2025

$1.60B

1,595,200,000 USD

Edwards Lifesciences Corp reported Operating cash flow of $1.6B for fiscal year 2025 in its 10-K filed Feb 25, 2026.

Fiscal period: 2025 FY
Period end: 2025-12-31
Form: 10-K
Filed: Feb 25, 2026
Entity (CIK): 0001099800

Provenance trail

Filed with the SEC
Form 10-K, filed Feb 25, 2026.
Accession 0001099800-26-000009
Open in the Inline XBRL viewer for 0001099800-26-000009
Reported in the filing
Operating cash flow for fiscal year 2025, the period ended 2025-12-31, in USD. Valuein maps the filed line to the standard concept OperatingCashFlow.
Stored as one fact row
Every channel returns this row with the same id.
fact_id 437ba91e6f5ffc37a47c7c412e31767e2521105a01623b298e62dee81e017b4e
Shown on this page
The same $1.60B appears in the Cash Flow Statement and in Cash & capital allocation.

fact rowjson

{  "entity_id": "0001099800",  "standard_concept": "OperatingCashFlow",  "fiscal_year": 2025,  "fiscal_period": "FY",  "period_end": "2025-12-31",  "numeric_value": 1595200000,  "unit": "USD",  "accession": "0001099800-26-000009",  "fact_id": "437ba91e6f5ffc37a47c7c412e31767e2521105a01623b298e62dee81e017b4e"}

Get the same data

Get your free API key

bash

# Fact-level Parquet over HTTPS, every row traced to its filingcurl -H "Authorization: Bearer $VALUEIN_API_KEY" \  https://data.valuein.biz/v1/pro/fact/0001099800.parquet \  -o ew.parquet

Read the API docs

Terminalbash

# The same tables in your notebooks and backtests; the free sample needs no token$ pip install valuein-sdk

Python

from valuein_sdk import ValueinClient with ValueinClient() as client:    sql = """        SELECT fiscal_year, numeric_value FROM fact        WHERE entity_id = '0001099800'          AND standard_concept = 'TotalRevenue'          AND fiscal_period = 'FY'    """    print(client.run_query(sql))

Install the SDK

bash

# Connect Claude or ChatGPT to the same facts, each with a fact_idhttps://mcp.valuein.biz/mcp Ask your agent:get_company_fundamentals EW   # CIK 0001099800

Connect the MCP server

bash

# Ask in plain English; every figure comes back cited to its filingTell me about EW: a quick, cited overview I can dig into.

Open EW in Workspace

One token unlocks every channel. SDK docs · MCP docs

Cite this page

Data as of Oct 31, 2026. Canonical address: https://valuein.biz/data/EW

APA-style text

Valuein. (2026, October 31). Edwards Lifesciences Corp (EW) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/EW

BibTeX

@misc{valuein_ew_2026,
  author = {{Valuein}},
  title = {Edwards Lifesciences Corp (EW) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/EW}},
  note = {Data as of 2026-10-31; source: SEC EDGAR filings}
}

Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 25, 2026 · accession 0001099800-26-000009

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

View EW filings on SEC EDGAR

Index names are trademarks of their owners; Valuein is not affiliated with or endorsed by any index provider.

At a glance

Growth

Profitability

Per share

Insiders & holders

02Financial statements

Income Statement

Balance Sheet

Cash Flow Statement

Ratios & valuation

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Smart money

Jul 31, 2024 · 10-Q

Feb 28, 2025 · 10-K

May 6, 2025 · 10-Q

Feb 25, 2026 · 10-K

06Peers, filings & research

Sector Peers

Recent SEC filings

Research Reports

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for Edwards Lifesciences Corp

Provenance trail

Get the same data

08Cite this page

Insiders & holders

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Jul 31, 2024 · 10-Q

Feb 28, 2025 · 10-K

May 6, 2025 · 10-Q

Feb 25, 2026 · 10-K

Sector Peers

Recent SEC filings

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for Edwards Lifesciences Corp

Provenance trail

Get the same data

Financial statements

Cash & capital allocation

Smart money

Peers, filings & research

The data behind this page

Cite this page

Cash & capital allocation

Smart money

The data behind this page